What Is SS-31 (Elamipretide)? Benefits, Uses & Research

A physician-guided look at SS-31, also called elamipretide: how this mitochondria-targeted peptide interacts with cardiolipin, its FDA-approved use, potential benefits, safety and what human research actually shows.

What Is SS-31 (Elamipretide)?

SS-31 belongs to the Szeto–Schiller family of aromatic-cationic peptides. Its sequence is D-Arg–dimethylTyr–Lys–Phe-NH₂. Unlike many compounds that depend on mitochondrial membrane potential to concentrate inside mitochondria, elamipretide can localize to mitochondrial membranes even when membrane potential is impaired.

That unusual targeting has made SS-31 peptide a major research topic in mitochondrial biology. The molecule has been investigated in Barth syndrome, primary mitochondrial myopathy, heart failure, age-related mitochondrial dysfunction and other conditions in which impaired mitochondrial energetics may contribute to disease.

How Does SS-31 Work?

The mechanism is more nuanced than calling SS-31 simply an “antioxidant peptide.” Contemporary research suggests its effects arise from modifying the mitochondrial membrane environment and cardiolipin-associated protein function rather than merely scavenging free radicals.

Cardiolipin is concentrated in the inner mitochondrial membrane and helps organize respiratory-chain complexes, maintain cristae structure and support cytochrome c function. When cardiolipin becomes abnormal or oxidized, electron transport can become less efficient, reactive oxygen species may rise and ATP generation can decline.

What Are the Potential Benefits of SS-31?

When people search for SS-31 benefits or elamipretide benefits, the evidence needs to be separated into three categories:

• FDA-approved benefit: improvement in muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg.
• Human research: studies in primary mitochondrial myopathy, older adults, heart failure and other disease states have explored mitochondrial energetics, exercise tolerance and symptoms, with mixed results.
• Preclinical research: extensive laboratory and animal data explore oxidative stress, cardiac function, skeletal muscle, kidney injury, neurobiology and aging.

This distinction is important because a compelling mitochondrial mechanism does not automatically establish meaningful clinical benefit in healthy adults.

Is SS-31 FDA Approved?

The FDA approval was a major milestone because Forzinity became the first approved treatment for Barth syndrome. Barth syndrome is a rare genetic mitochondrial disorder in which abnormal cardiolipin metabolism contributes directly to impaired mitochondrial structure and function.

FDA based accelerated approval on improvement in knee extensor muscle strength, considered an intermediate clinical endpoint reasonably likely to predict patient benefit. A confirmatory randomized trial is required to verify clinical benefit.

What Did the Barth Syndrome Research Show?

The FDA Drug Trials Snapshot describes a small study involving 12 patients with genetically confirmed Barth syndrome. During the randomized crossover phase, elamipretide did not outperform placebo on the primary endpoints of six-minute walking distance or total fatigue score.

However, improvement in knee extensor muscle strength was observed during the longer open-label extension. FDA considered that intermediate endpoint reasonably likely to predict meaningful patient benefit and granted accelerated approval while requiring post-approval confirmation.

That nuance is important for an evidence-based discussion: SS-31 has real FDA-approved clinical status, but the approval is narrow and the evidence base is still evolving.

What Does Research Show for Primary Mitochondrial Myopathy?

This trial is particularly important because it prevents overgeneralizing SS-31 as a universal mitochondrial-performance therapy.

In MMPOWER-3, 218 adults with genetically confirmed primary mitochondrial myopathy were randomized to elamipretide or placebo. The trial failed both primary efficacy endpoints: there was no significant improvement in six-minute walk distance and no significant improvement in the study’s total fatigue score.

Later subgroup analyses have raised hypotheses about whether genetic subtypes may respond differently, but those analyses do not overturn the overall negative Phase 3 result and require prospective confirmation.

Does SS-31 Increase ATP or Improve Mitochondrial Energy?

One small randomized study in older adults reported a rapid increase in skeletal-muscle mitochondrial ATP production capacity after a single dose of elamipretide, supporting biological activity in human muscle.

That is scientifically interesting, but improving a mitochondrial laboratory endpoint is not the same as proving that a treatment improves fatigue, athletic performance or quality of life. Clinical outcomes must be demonstrated separately.

SS-31 for Anti-Aging, Energy and Recovery: What Is Actually Known?

Interest in SS-31 for anti-aging comes partly from animal studies showing improvements in age-associated mitochondrial function, redox balance and cardiac or skeletal-muscle physiology.

Those studies help identify biological pathways worth investigating. They do not establish a proven longevity treatment in humans. There is currently no evidence that elamipretide extends human lifespan, reverses biological aging or provides predictable performance enhancement in healthy individuals.

SS-31 Side Effects and Safety

Across clinical programs, injection-site reactions have been common and are generally described as mild to moderate. The current FDA label also warns about hypersensitivity reactions, including serious events.

Because an FDA-approved elamipretide product now exists for a defined indication, online material referring to SS-31 simply as a generic “research peptide” can be misleading. Forzinity is an FDA-approved prescription drug for a narrow indication; that does not validate unapproved formulations or uses marketed elsewhere.

SS-31 vs MOTS-c: What’s the Difference?

A useful simplified distinction is that SS-31 is primarily studied as a mitochondrial membrane and bioenergetic therapeutic, while MOTS-c is studied more as a mitochondrial metabolic signaling peptide. Both areas are scientifically active, but they have very different levels of human evidence and regulatory status.

SS-31 vs Humanin: What’s the Difference?

Humanin was identified during research into neuronal cell survival and has since been investigated across numerous preclinical models. Its biology is compelling, but it remains much earlier clinically than elamipretide.

This difference is why mitochondrial peptides should not be grouped together as if they were interchangeable therapies.

SS-31 (Elamipretide) in Dallas: What Patients Should Know

At Sanjiva Medical Spa in Dallas, emerging peptide topics are approached through medical evaluation and evidence review rather than simply matching a symptom to a peptide.

Fatigue, reduced exercise tolerance, poor recovery or changes in body composition can result from many causes—including sleep disorders, nutritional factors, metabolic disease, medication effects, cardiopulmonary disease, endocrine disorders and deconditioning. A mitochondrial explanation should not be assumed without appropriate evaluation.

Frequently Asked Questions About SS-31